Semaglutide CAS NO.910463-68-2

Semaglutide has a significant and lasting glucose-lowering effect. While lowering blood sugar, it can also effectively reduce weight and significantly improve blood lipid profiles, lower triglyceride and low-density lipoprotein cholesterol levels, and increase high-density lipoprotein cholesterol levels, thereby reducing the risk of cardiovascular disease.

Semaglutide is suitable for a wide range of people, and can exert significant therapeutic effects regardless of whether the patient has complications such as obesity and dyslipidemia. In addition, Semaglutide does not rely on insulin secretion, so it is suitable for diabetic patients with poor pancreatic function. At the same time, Semaglutide has good safety and fewer adverse reactions.